Fulcrum Therapeutics announced a significant business restructure. The company is reducing its workforce by 85%. This leaves the company with nine employees. The decision follows the discontinuation of its lead dr-g candidate, pociredir. The FDA raised safety concerns regarding the sickle cell disease treatment.
https://www.biospace.com/business/fulcrum-tanks-as-cancer-concerns-stymie-sickle-cell-asset-trigger-business-reorg